

# Journal of Medical Microbiology

## Rapid Phenotypic Detection of AmpC $\beta$ -Lactamases, Extended-Spectrum- $\beta$ -Lactamases and Metallo- $\beta$ -Lactamases in Enterobacteriaceae Using A Resazurin Microtitre Assay with Inhibitor-Based Methods

--Manuscript Draft--

<b>Manuscript Number:</b>	JMM-D-16-00264
<b>Full Title:</b>	Rapid Phenotypic Detection of AmpC $\beta$ -Lactamases, Extended-Spectrum- $\beta$ -Lactamases and Metallo- $\beta$ -Lactamases in Enterobacteriaceae Using A Resazurin Microtitre Assay with Inhibitor-Based Methods
<b>Short Title:</b>	AmpC, ESBL and MBL Detection Using Resazurin
<b>Article Type:</b>	Standard
<b>Section/Category:</b>	Clinical Microbiology
<b>Keywords:</b>	Phenotypic Detection, $\beta$ -lactamases, Resazurin, Enterobacteriaceae.
<b>Corresponding Author:</b>	Katie Evans Liverpool John Moores University Liverpool, UNITED KINGDOM
<b>First Author:</b>	Yothin Teethaisong
<b>Order of Authors:</b>	Yothin Teethaisong Griangsak Eumkeb Sakesit Chumnarnsilpa Nongluk Autarkool Jon Hobson Ismini Nakouti Glyn Hobbs Katie Evans
<b>Manuscript Region of Origin:</b>	UNITED KINGDOM
<b>Abstract:</b>	Dissemination of antibiotic resistance in Enterobacteriaceae mediated by AmpC, ESBL and MBL $\beta$ -lactamases is clinically significant. A simple, rapid method for the detection of these resistance phenotypes would greatly improve chemotherapeutic recommendation. This technology would provide valuable input in our surveillance of resistance on a global stage, particularly if the methodology could be applicable to resource poor settings. A resazurin microtitre plate (RMP) assay incorporating cloxacillin (CX), clavulanic acid (CA), and EDTA for the rapid phenotypic identification of AmpC, ESBL, MBL and the co-existence of $\beta$ -lactamases has been developed. A total of 44 molecularly characterised Enterobacteriaceae clinical isolates producing AmpCs, ESBLs, co-producers of ESBL and AmpC, MBLs, and co-producers of ESBL and MBL were phenotypically examined using the RMP assay. The ceftazidime (CAZ)-based and cefotaxime (CTX)-based RMP assay successfully detected all 15 AmpC, 12 ESBL, 9 MBL producers, 6 ESBL-AmpC co-producers, and 2 ESBL-MBL co-producers without false positive results. The CAZ-based assay was more reliable in detecting AmpC alone, while the CTX-based assay performed better in identifying co-producers of ESBL and AmpC. There was no difference in detection of ESBL and MBL producers. The findings of the present study suggest that use of the RMP assay with particular $\beta$ -lactamase inhibitors explicitly detects three different $\beta$ -lactamases, as well as co-existence of $\beta$ -lactamases within 6 h. This assay is applicable to carry out in any laboratory, is cost-effective and easy to interpret. It could be implemented in screening patients, controlling infection and for surveillance purposes.

Rapid Phenotypic Detection of AmpC  $\beta$ -Lactamases, Extended-Spectrum-  $\beta$ -Lactamases and Metallo- $\beta$ -Lactamases in Enterobacteriaceae Using A Resazurin Microtitre Assay with Inhibitor-Based Methods

Running title: AmpC, ESBL and MBL Detection Using Resazurin

Yothin Teethaisong<sup>1,2</sup>, Griangsak Eumkeb<sup>2</sup>, Sakesit Chumnarnsilpa<sup>3</sup>, Nongluk Autarkool<sup>4</sup>, Jon Hobson<sup>5</sup>, Ismini Nakouti<sup>1</sup>, Glyn Hobbs<sup>1</sup>, Katie Evans<sup>1\*</sup>

<sup>1</sup> School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom

<sup>2</sup> School of Pharmacology, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand

<sup>3</sup> School of Biochemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, 30000, Thailand

<sup>4</sup> Faculty of Medical Science, Nakhon Ratchasima College, Nakhon Ratchasima, 30000, Thailand

<sup>5</sup> Mast Group Ltd, Bootle, Liverpool, L20 1EA, United Kingdom

\* Address correspondence to Katie Evans

Email: K.Evans@ljmu.ac.uk, Tel.: +44-01512312334

**Keywords:** Phenotypic Detection,  $\beta$ -lactamases, Resazurin, Enterobacteriaceae.

## Abstract

Dissemination of antibiotic resistance in Enterobacteriaceae mediated by AmpC, ESBL and MBL  $\beta$ -lactamases is clinically significant. A simple, rapid method for the detection of these resistance phenotypes would greatly improve chemotherapeutic recommendation. This technology would provide valuable input in our surveillance of resistance on a global stage, particularly if the methodology could be applicable to resource poor settings. A resazurin microtitre plate (RMP) assay incorporating cloxacillin (CX), clavulanic acid (CA), and EDTA for the rapid phenotypic identification of AmpC, ESBL, MBL and the co-existence of  $\beta$ -lactamases has been developed. A total of 44 molecularly characterised Enterobacteriaceae clinical isolates producing AmpCs, ESBLs, co-producers of ESBL and AmpC, MBLs, and co-producers of ESBL and MBL were phenotypically examined using the RMP assay. The ceftazidime (CAZ)-based and cefotaxime (CTX)-based RMP assay successfully detected all 15 AmpC, 12 ESBL, 9 MBL producers, 6 ESBL-AmpC co-producers, and 2 ESBL-MBL co-producers without false positive results. The CAZ-based assay was more reliable in detecting AmpC alone, while the CTX-based assay performed better in identifying co-producers of ESBL and AmpC. There was no difference in detection of ESBL and MBL producers. The findings of the present study suggest that use of the RMP assay with particular  $\beta$ -lactamase inhibitors explicitly detects three different  $\beta$ -lactamases, as well as co-existence of  $\beta$ -lactamases within 6 h. This assay is applicable to carry out in any laboratory, is cost-effective and easy to interpret. It could be implemented in screening patients, controlling infection and for surveillance purposes.

## 49 Introduction

50 Infections caused by multidrug-resistant Enterobacteriaceae are among one of the most  
 51 serious threats to human health (Tangden & Giske,2015). The production of  $\beta$ -lactamases  
 52 mediated by both chromosomal and plasmid genes are crucial mechanisms of antibiotic  
 53 resistance. AmpC  $\beta$ -lactamases were the first bacterial enzymes found to inactivate penicillin,  
 54 first identified in *Escherichia coli* in 1940 prior to penicillins being medically introduced  
 55 (Jacoby,2009). Plasmid-mediated AmpC  $\beta$ -lactamase (pAmpC)-producing  
 56 Enterobacteriaceae can confer resistance to multiple antibiotics, such as penicillins,  
 57 oxyimino-cephalosporins (e.g. cefotaxime, ceftazidime and ceftriaxone) and 7- $\alpha$ -  
 58 methoxycephalosporins (e.g. cefoxitin and cefotetan) (Gupta *et al.*,2012). CMY-type  $\beta$ -  
 59 lactamases, especially CMY-2 are the highest prevalence of pAmpC in *E. coli* that have been  
 60 commonly identified in many regions of the world (Doi *et al.*,2010; Liebana *et al.*,2013).  
 61 These enzymes are inhibited by boronic acid (BA), and its derivatives (Beesley *et al.*,1983)  
 62 and cloxacillin (CX) (Jacoby,2009). AmpC  $\beta$ -lactamases are poorly inhibited by clavulanic  
 63 acid (CA) (Bush *et al.*,1995).

64 Enterobacteriaceae can also produce powerful enzymes called extended-spectrum  $\beta$ -  
 65 lactamases (ESBLs), which characteristically confer resistance to penicillins, cephalosporins,  
 66 and monobactams, but remain susceptible to  $\beta$ -lactamase inhibitors (CA, tazobactam,  
 67 sulbactam) cephamycins and carbapenems (Bradford,2001). The majority of ESBL-  
 68 producing clinical isolates of Enterobacteriaceae harbour TEM-, SHV-, and CTX-M-type  $\beta$ -  
 69 lactamases. These enzymes have gained medical significance in both hospital and community  
 70 settings, across all ages and demographics (Lukac *et al.*,2015). Furthermore, carbapenem-  
 71 inactivating  $\beta$ -lactamase, namely metallo- $\beta$ -lactamase (MBL) has been identified with  
 72 increasing prevalence over the past few years (Patrice *et al.*,2011). MBL can hydrolyse all  
 73 classes of bicyclic  $\beta$ -lactams (penicillins, cephalosporins and carbapenems) and all

commercially available  $\beta$ -lactamase inhibitors (such as CA), but lack hydrolytic activity toward monocyclic  $\beta$ -lactams (monobactams) (Bebrone,2007). The activity of this enzyme is facilitated by zinc-ions to degrade  $\beta$ -lactams and is inhibited by metal-chelating ethylenediaminetetraacetic acid (EDTA) and dipicolinic acid (Walsh *et al.*,2005). Imipenemase (IMP), Verona integron-encoded metallo- $\beta$ -lactamase (VIM), and New Delhi metallo- $\beta$ -lactamase (NDM) are common widespread MBLs. These metalloenzymes were frequently identified in *Pseudomonas aeruginosa* and *Acinetobacter* spp., but currently an increasing emergence of these have been documented in Enterobacteriaceae worldwide (Patel & Bonomo,2013).

The early detection of the presence of these resistant strains at the phenotypic level would aid infection-control practitioners to minimise the dissemination of these bacteria and also help to select appropriate antimicrobial treatment (Pitout & Laupland,2008). The development of a rapid method for the identification of these  $\beta$ -lactamase producing strains in clinical practice is a challenging issue. The resazurin (Alamar blue) reduction assay is a simple and inexpensive colorimetric method that has extensively been used as an indicator for cell growth, cell viability, toxicity and indirect antimicrobial susceptibility testing. This dye is non-toxic to cells and stable in culture media. A blue coloured resazurin is irreversibly converted to a pink coloured resorufin by active cells (O'Brien *et al.*,2000; Palomino *et al.*,2002). The present study uses the resazurin dye in conjunction with three distinct  $\beta$ -lactamase inhibitors, CX, CA, and EDTA, for the phenotypic detection of AmpC, ESBL, MBL and co-expression of  $\beta$ -lactamases.

## Methods

### Bacterial Isolates, Chemicals and Antibiotics

A total of 44 Enterobacteriaceae clinical isolates were used in this study. The bacterial strains included *E. coli* (n=13), *Klebsiella pneumoniae* (n=16), *Enterobacter aerogenes* (n=2), *Enterobacter cloacae* (n=8), *Morganella morganii* (n=1), *Citrobacter freundii* (n=3), and *Klebsiella ozaenae* (n=1); 15 were AmpC producers, 12 were ESBL producers, 6 were ESBL and AmpC co-producers, 9 were MBL producers, and 2 were ESBL and MBL co-producers (Table 1). The control strains were *E. coli* ATCC 25922 (non- $\beta$ -lactamase producer), *E. cloacae* ATCC BAA-1143 (*bla*<sub>ACT-32</sub>), *E. coli* NCTC 13352 (*bla*<sub>TEM-10</sub>) and *E. coli* NCTC 13353 (*bla*<sub>CTX-M-15</sub>). All organisms had been identified by biochemical, phenotypic and molecular tests including combined disc, PCR and sequencing methods as previously described (Pérez-Pérez & Hanson,2002; Woodford,2010; Roschanski *et al.*,2014). All antibiotics and chemicals employed were purchased from Sigma Aldrich, UK. Mueller-Hinton Broth (MHB) powder was obtained from Scientific Laboratory Supplies, UK. Antibiotics and  $\beta$ -lactamase inhibitors were prepared in accordance with the recommendation of manufacturers.

#### **Resazurin Microtitre Plate Assay (RMP)**

The production of ESBL, AmpC, MBL and co- $\beta$ -lactamases was phenotypically detected using the RMP assay based upon the broth microdilution method. An overnight culture of the appropriate test bacterium was pelleted for 10 min and washed twice with normal saline at 4,000 rpm for 5 min before adjustment to a 0.5 McFarland suspension according to the recommendations of the Clinical Laboratory Standards Institute (CLSI) in document M07-A9 (Clinical Laboratory Standards Institute,2012). An aliquot (20  $\mu$ L) of a  $5 \times 10^6$  CFU/mL of organism were added to the wells containing 180  $\mu$ L of MHB, amended with resazurin at a concentration of 20  $\mu$ g/mL, and serial twofold dilution of cefotaxime (CTX) or ceftazidime (CAZ) with a fixed concentration of  $\beta$ -lactamase inhibitors; CX at 200  $\mu$ g/mL, EDTA at 0.5 mM, and CA at 4  $\mu$ g/mL. Following incubation at 37 °C, the lowest concentration showing

no colorimetric change from blue to pink within 6 h was considered as the MIC value. Interpretation criteria of the result obtained is explained in Table 2. The experiment was carried out in three independent replicates.

## Results and Discussion

$\beta$ -Lactam antibiotics are most frequently prescribed for the treatment of infections caused by Gram negative bacteria, in particular Enterobacteriaceae. Resistance to  $\beta$ -lactams is mediated by both plasmid- and chromosomally-encoded  $\beta$ -lactamases. The rapid global spread of these resistant bacteria is facilitated by inter- and intra-species gene transmission, poor sanitation and hygiene, increasing global trade, international travel and tourism, and antibiotic misuse (Rogers *et al.*,2011; Aung *et al.*,2012; Laxminarayan *et al.*,2013). The consequence is increased treatment failure and health risks. The development of rapid and accurate methods for the detection and characterisation of different types of  $\beta$ -lactamase remains an urgent necessity. The early detection is crucial in guiding appropriate antimicrobial therapy. The common conventional detection methods for the production of  $\beta$ -lactamase are still time-consuming (approximately 24 to 48 h) (Nordmann *et al.*,2012). Here, we developed the RMP assay with inhibitor-based methods for the early phenotypic detection of ESBL, AmpC, MBL, and co-production of  $\beta$ -lactamases.

The findings from the RMP assay were very simple and clear to interpret as illustrated in Figure 1. The results showed that the RMP CAZ-based assay was more reliable than the CTX-based assay for early AmpC detection. An eightfold or higher MIC ratio was observed when comparing the well without CX to other wells only for AmpC producers. Other MIC ratios revealed values lower than 8, which indicated negative results for ESBL and MBL producers. The CAZ-based assay successfully detected 15 of all 15 AmpC-producing

isolates, while 14 of 15 strains were detected by the CTX-based RMP assay. The AmpC control strain clearly showed hyperproduction of AmpC  $\beta$ -lactamase indicated by a high MIC value in the well without an AmpC inhibitor (Table 1). The production of AmpC  $\beta$ -lactamase in Gram negative pathogens, especially Enterobacteriaceae is clinically important. Accurate and rapid detection methods for these enzymes should be urgently developed. This would ensure effective antimicrobial therapy and improve clinical management as a consequence of clinical failure in the treatment of AmpC producers with broad-spectrum cephalosporins (Polsfuss *et al.*,2011). Cloxacillin is well-described as an AmpC  $\beta$ -lactamase inhibitor, but it cannot distinguish between plasmid-mediated and chromosome-borne AmpC (Jacoby,2009). This study found that CAZ in conjunction with CX and EDTA was more sensitive for early detection of AmpC-producing Enterobacteriaceae compared with the CTX-based assay. This result is consistent with a previous report where CAZ showed the best performance compared with CTX, cefmetazole, or moxalactam in combination with 3-aminophenylboronic acid (APB) in detection of AmpC  $\beta$ -lactamases (Yagi *et al.*,2005). Another previous research study reported no difference in sensitivity and specificity between CTX- and CAZ-based detection in the presence of CA with and without BA in detection of pAmpC (Jeong *et al.*,2009). In this study, some AmpC producers such as, *K. pneumoniae* 2001 (DHA-1), *E. coli* 2002 (DHA-1), and *M. morganii* 2010 were partially inhibited by CX as indicated by the high MIC values after exposure to CX. In those isolates we suggest that the resistance was not only mediated by AmpC  $\beta$ -lactamase, but might also be conferred by alteration in the permeability of the outer membrane.

The MIC ratio for wells without CA compared to wells with CA gave a value  $\geq 8$  in all tested ESBL-producing Enterobacteriaceae employed in this study. The findings unambiguously indicated that both CAZ-based and CTX-based assays gave reproducible results in detecting all ESBL isolates. Even though CLSI has recommended a standardised confirmatory test for



ESBL-producing Enterobacteriaceae, previous reports found that using CTX and CAZ alone and in combination with CA demonstrated a high percentage of false-negative results in detection of ESBL producers due to co-production of  $\beta$ -lactamase enzymes (Jeong *et al.*,2009). In the current study inhibitor-based methods using three different  $\beta$ -lactamase inhibitors were applied to improve the sensitivity and specificity for phenotypic detection of ESBL in clinical isolates of Enterobacteriaceae. This modification allows the successful identification of all ESBLs in both CAZ-and CTX-based assays. Several techniques for detecting the production of ESBL have been proposed such as, double-disc synergy test, Etest and automated methods. The sensitivities and specificities for the double-disc test and Etest were 80% to 95%, whilst automated susceptibility methods were 80% to 99% (Drieux *et al.*,2008; Gazin *et al.*,2012). In addition, the ESBL NDP (Nordmann/Dortet/Poirel) test has been developed for rapid detection with an excellent sensitivity and specificity of 92.6% and 100%, respectively. However, this test was limited to detecting ESBL without presence of AmpC or other  $\beta$ -lactamases (Nordmann *et al.*,2012).

All MBL producers were detected by the RMP assay, including 9 MBL-producing isolates and 2 co-producers of ESBL and MBL. The CTX-based assay gave similar results with the CAZ-based assay for the rapid phenotypic detection of MBL producers. The MIC ratio of non- $\beta$ -lactamase-producing *E. coli* ATCC 25922 for both CTX- and CAZ-based assays was 1, suggesting no ESBL, AmpC, and MBL production in this bacterium. A raised global dissemination of MBL-producing Enterobacteriaceae has drawn researchers to develop reliable techniques for detection of MBLs (Hattori *et al.*,2013). Yan and colleagues conducted double-disc, combined disc, and Etest techniques for the detection of Gram negative bacilli producing MBLs. They found that the 2-mercaptopropionic acid (2-MPA) double-disc test using CAZ and cefepime, with and without CA, exhibited highest sensitivity (100%) compared with the combined disc test (86.7%) and Etest (36.7%). Even the double-

disc test showed high sensitivity, but there were some disadvantages, including subjective interpretation of results in some samples, and also volatile and odorous properties of 2-MPA (Yan *et al.*,2004). More recently, double-disc synergy tests using sodium mercaptoacetic acid (SMA) and EDTA as MBL inhibitors, and CAZ, imipenem and meropenem as indicator antibiotics have emerged. The results showed that CAZ in combination with SMA can detect only MBL-producing strains, whereas a combination of meropenem and SMA revealed the best performance (sensitivity, 79.1%; specificity, 100%) in detection of co-production of  $\beta$ -lactamases (Hattori *et al.*,2013). Yagi and colleagues also suggested the broth microdilution method incorporating CAZ or CTX with SMA for successful detection of IMP-type MBL (Yagi *et al.*,2005). Our findings revealed a good performance in the RMP assay for either MBL alone or in combination with ESBL.

ESBL and AmpC co-producers were positively detected as indicated by a  $\geq 8$  MIC ratio for wells containing either CA or CX compared to wells containing both CA and CX. The CTX-based RMP assay was more reliable in phenotypic characterisation of the co-existence of ESBL and AmpC  $\beta$ -lactamase compared with the CAZ-based RMP assay (Table 1). Co-production of different types of  $\beta$ -lactamase in the same strain are one of the most common causes of phenotypic detection failure. The most prevalent isolates co-producing pAmpCs and ESBLs are *K. pneumoniae* and *E. coli* (Goossens & Grabein,2005). These co- $\beta$ -lactamases may result in false-negative tests for the detection of ESBLs or AmpCs (Coudron,2005). A method that can distinguish between ESBLs and pAmpCs is important for both treatment and epidemiology (Song *et al.*,2007). Furthermore, co-expression of MBL together with ESBLs (commonly CTX-M-type) and AmpC  $\beta$ -lactamases (mostly CMY-enzymes) appears to be difficult to detect. Consequently, these may be a major cause of false-negative tests for detection of co-MBL, AmpC and ESBL in Gram negative pathogens (Hattori *et al.*,2013; Tangden & Giske,2015).

Although simple phenotypic tests for ESBL, AmpC and MBL have been proposed by several researchers, and indeed conducted in clinical laboratory practice (Yagi et al.,2005; Jeong et al.,2009), there is no standard guideline for phenotypic detection of AmpC that has been recommended by the CLSI (Clinical Laboratory Standards Institute,2012). Broth microdilution methods have become more popular in clinical diagnostic laboratories since semi-automated antimicrobial susceptibility test systems have become commercially available. This test generally involves overnight incubation in the determination of antibiotic susceptibility profiling (Yagi et al.,2005). The present study using the RMP assay allows for the detection of ESBLs, AmpCs, MBLs and co-producers within 6 h. RMP assays could allow clinicians to detect these enzymes in rural clinical laboratories in resource poor settings.

Phenotypic tests for  $\beta$ -lactamase production are carried out in most clinical diagnostic laboratories because they are easy to implement and are cost effective. This detection is important in terms of epidemiological purposes and to restrict the dissemination of  $\beta$ -lactamase-mediated resistance mechanisms (Poulou et al.,2014). Phenotypic tests alone cannot distinguish between the specific *bla* genes of  $\beta$ -lactamases (TEM, SHV, CTX for ESBLs, CMY, MOX for AmpCs, and IMP, NDM, VIM for MBLs) (Pitout & Laupland,2008; Pitout et al.,2010), therefore, several reference laboratories use molecular methods for identification of those  $\beta$ -lactamase-encoded genes. Molecular approaches are restricted largely to reference laboratories for epidemiological studies because of the complexity and diversity of distinct point mutations of  $\beta$ -lactamases (Sundsfjord et al.,2004).

Although we used small samples of clinical isolates, a previous study found that use of CTX or CAZ combined with CA for detecting ESBL and CTX or CAZ plus BA for identifying pAmpC demonstrated 100% in both sensitivity and specificity (Jeong et al.,2009). In our study, the RMP assay detected all ESBL, AmpC, and ESBL-AmpC co-producers. Therefore,

we expect that our RMP assay could reach 100% in sensitivity and specificity similar to previous reports when a larger number of clinical isolates are tested. This assay can successfully distinguish co-expression of ESBL and AmpC or ESBL and MBL in the same strain. In future work, isolates with other resistance mechanisms, including alteration of permeability of bacterial membrane and modification of membrane proteins should be included in total isolates screened with RMP assay. The early detection of  $\beta$ -lactamase enzymes may reduce a delay in the initiation of appropriate antimicrobial therapy and could produce effective treatment. RMP assay is a useful method that can detect and characterise ESBL, AmpC, MBL and co-production of ESBL and AmpC or ESBL and MBL within 6 h. It could be implemented in microbiological diagnostic laboratories in resource poor areas to help clinicians screen patients, control infection, and provide epidemiological surveillance.

## **Acknowledgements**

This work was supported by Thailand Research Fund through The Royal Golden Jubilee Ph.D. Programme (Grant No. PHD/0125/2554) and British Council Thailand via Newton Fund: PhD placement. We thank Lynne Wylie, a technical co-ordinator at LJMU, for kind assistance in sub culture of the organisms used in the present study. We would also like to express our appreciation to Suranaree University of Technology and Liverpool John Moores University for the facilities to carry out this project.

## **Transparency declaration**

The authors have no conflict of interest to declare.

## References

- Aung, A. K., Skinner, M. J., Lee, F. J. & Cheng, A. C. (2012).** Changing epidemiology of bloodstream infection pathogens over time in adult non-specialty patients at an Australian tertiary hospital. *Commun Dis Intell Q Rep* **36**(4), E333-341.
- Bebrone, C. (2007).** Metallo- $\beta$ -lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. *Biochem Pharmacol* **74**(12), 1686-1701.
- Beesley, T., Gascoyne, N., Knott-Hunziker, V., Petursson, S., Waley, S. G., Jaurin, B. & Grundström, T. (1983).** The inhibition of class C beta-lactamases by boronic acids. *Biochem J* **209**(1), 229-233.
- Bradford, P. A. (2001).** Extended-Spectrum  $\beta$ -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clin Microbiol Rev* **14**(4), 933-951.
- Bush, K., Jacoby, G. A. & Medeiros, A. A. (1995).** A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* **39**(6), 1211-1233.
- Clinical Laboratory Standards Institute (2012).** Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. *CLSI document M7-A7, Ninth Edition*. Wayne, L.Z. Pennsylvania, Clinical and Laboratory Standards Institute. **26**: 14-34.
- Coudron, P. E. (2005).** Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in *Klebsiella* spp., *Escherichia coli*, and *Proteus mirabilis*. *J Clin Microbiol* **43**(8), 4163-4167.
- Doi, Y., Paterson, D. L., Egea, P., Pascual, A., Lopez-Cerero, L., Navarro, M. D., Adams-Haduch, J. M., Qureshi, Z. A., Sidjabat, H. E. & Rodriguez-Bano, J.**

- 294           **(2010).** Extended-spectrum and CMY-type beta-lactamase-producing *Escherichia coli*  
 295           in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. *Clin*  
 296           *Microbiol Infect* **16**(1), 33-38.
- 297   **Drieux, L., Brossier, F., Sougakoff, W. & Jarlier, V. (2008).** Phenotypic detection of  
 298           extended-spectrum beta-lactamase production in Enterobacteriaceae: review and  
 299           bench guide. *Clin Microbiol Infect* **14 Suppl 1**, 90-103.
- 300   **Gazin, M., Paasch, F., Goossens, H. & Malhotra-Kumar, S. (2012).** Current trends in  
 301           culture-based and molecular detection of extended-spectrum-beta-lactamase-  
 302           harboring and carbapenem-resistant Enterobacteriaceae. *J Clin Microbiol* **50**(4), 1140-  
 303           1146.
- 304   **Goossens, H. & Grabein, B. (2005).** Prevalence and antimicrobial susceptibility data for  
 305           extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from  
 306           the MYSTIC Program in Europe and the United States (1997-2004). *Diagn Microbiol*  
 307           *Infect Dis* **53**(4), 257-264.
- 308   **Gupta, V., Kumarasamy, K., Gulati, N., Garg, R., Krishnan, P. & Chander, J. (2012).**  
 309           AmpC  $\beta$ -lactamases in nosocomial isolates of *Klebsiella pneumoniae* from India.  
 310           *Indian J Med Res* **136**(2), 237-241.
- 311   **Hattori, T., Kawamura, K. & Arakawa, Y. (2013).** Comparison of test methods for  
 312           detecting metallo-beta-lactamase-producing Gram-negative bacteria. *Jpn J Infect Dis*  
 313           **66**(6), 512-518.
- 314   **Jacoby, G. A. (2009).** AmpC beta-lactamases. *Clin Microbiol Rev* **22**(1), 161-182.
- 315   **Jeong, S. H., Song, W., Kim, J. S., Kim, H. S. & Lee, K. M. (2009).** Broth microdilution  
 316           method to detect extended-spectrum beta-lactamases and AmpC beta-lactamases in  
 317           enterobacteriaceae isolates by use of clavulanic acid and boronic acid as inhibitors. *J*  
 318           *Clin Microbiol* **47**(11), 3409-3412.

- 319 **Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L.,**  
 320 **Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H. other authors**  
 321 **(2013).** Antibiotic resistance—the need for global solutions. *Lancet Infect Dis* **13**(12),  
 322 1057-1098.
- 323 **Liebana, E., Carattoli, A., Coque, T. M., Hasman, H., Magiorakos, A. P., Mevius, D.,**  
 324 **Peixe, L., Poirel, L., Schuepbach-Regula, G., Torneke, K. other authors (2013).**  
 325 Public health risks of enterobacterial isolates producing extended-spectrum beta-  
 326 lactamases or AmpC beta-lactamases in food and food-producing animals: an EU  
 327 perspective of epidemiology, analytical methods, risk factors, and control options.  
 328 *Clin Infect Dis* **56**(7), 1030-1037.
- 329 **Lukac, P. J., Bonomo, R. A. & Logan, L. K. (2015).** Extended-spectrum beta-lactamase-  
 330 producing Enterobacteriaceae in children: old foe, emerging threat. *Clin Infect Dis*  
 331 **60**(9), 1389-1397.
- 332 **Nordmann, P., Dortet, L. & Poirel, L. (2012).** Rapid detection of extended-spectrum-beta-  
 333 lactamase-producing Enterobacteriaceae. *J Clin Microbiol* **50**(9), 3016-3022.
- 334 **O'Brien, J., Wilson, I., Orton, T. & Pognan, F. (2000).** Investigation of the Alamar Blue  
 335 (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. *Eur J*  
 336 *Biochem* **267**(17), 5421-5426.
- 337 **Palomino, J. C., Martin, A., Camacho, M., Guerra, H., Swings, J. & Portaels, F. (2002).**  
 338 Resazurin microtiter assay plate: simple and inexpensive method for detection of drug  
 339 resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* **46**(8), 2720-  
 340 2722.
- 341 **Patel, G. & Bonomo, R. A. (2013).** "Stormy waters ahead": global emergence of  
 342 carbapenemases. *Front Microbiol* **4**, 48.


- 343 **Patrice, N., Thierry, N. & Laurent, P. (2011).** Global Spread of Carbapenemase-producing  
 344 Enterobacteriaceae. *Emerg Infect Diseases J* **17**(10), 1791-1798.
- 345 **Pérez-Pérez, F. J. & Hanson, N. D. (2002).** Detection of Plasmid-Mediated AmpC  $\beta$ -  
 346 Lactamase Genes in Clinical Isolates by Using Multiplex PCR. *Journal of Clinical*  
 347 *Microbiology* **40**(6), 2153-2162.
- 348 **Pitout, J. D. & Laupland, K. B. (2008).** Extended-spectrum beta-lactamase-producing  
 349 Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* **8**(3), 159-  
 350 166.
- 351 **Pitout, J. D., Le, P. G., Moore, K. L., Church, D. L. & Gregson, D. B. (2010).** Detection  
 352 of AmpC beta-lactamases in *Escherichia coli*, *Klebsiella* spp., *Salmonella* spp. and  
 353 *Proteus mirabilis* in a regional clinical microbiology laboratory. *Clin Microbiol Infect*  
 354 **16**(2), 165-170.
- 355 **Polsfuss, S., Bloemberg, G. V., Giger, J., Meyer, V., Böttger, E. C. & Hombach, M.**  
 356 **(2011).** Practical Approach for Reliable Detection of AmpC Beta-Lactamase-  
 357 Producing Enterobacteriaceae. *J Clin Microbiol* **49**(8), 2798-2803.
- 358 **Poulou, A., Grivakou, E., Vrioni, G., Koumaki, V., Pittaras, T., Pournaras, S. &**  
 359 **Tsakris, A. (2014).** Modified CLSI extended-spectrum beta-lactamase (ESBL)  
 360 confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae  
 361 producing various beta-lactamases. *J Clin Microbiol* **52**(5), 1483-1489.
- 362 **Rogers, B. A., Aminzadeh, Z., Hayashi, Y. & Paterson, D. L. (2011).** Country-to-country  
 363 transfer of patients and the risk of multi-resistant bacterial infection. *Clin Infect Dis*  
 364 **53**(1), 49-56.
- 365 **Roschanski, N., Fischer, J., Guerra, B. & Roesler, U. (2014).** Development of a multiplex  
 366 real-time PCR for the rapid detection of the predominant beta-lactamase genes CTX-  
 367 M, SHV, TEM and CIT-type AmpCs in Enterobacteriaceae. *PLoS One* **9**(7), e100956.



- Song, W., Bae, I. K., Lee, Y.-N., Lee, C.-H., Lee, S. H. & Jeong, S. H. (2007).** Detection of Extended-Spectrum  $\beta$ -Lactamases by Using Boronic Acid as an AmpC  $\beta$ -Lactamase Inhibitor in Clinical Isolates of *Klebsiella* spp. and *Escherichia coli*. *J Clin Microbiol* **45**(4), 1180-1184.
- Sundsford, A., Simonsen, G. S., Haldorsen, B. C., Haaheim, H., Hjelmvoll, S. O., Littauer, P. & Dahl, K. H. (2004).** Genetic methods for detection of antimicrobial resistance. *Apmis* **112**(11-12), 815-837.
- Tangden, T. & Giske, C. G. (2015).** Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. *J Intern Med* **277**(5), 501-512.
- Walsh, T. R., Toleman, M. A., Poirel, L. & Nordmann, P. (2005).** Metallo-beta-lactamases: the quiet before the storm? *Clin Microbiol Rev* **18**(2), 306-325.
- Woodford, N. (2010).** Rapid characterization of beta-lactamases by multiplex PCR. *Methods Mol Biol* **642**, 181-192.
- Yagi, T., Wachino, J., Kurokawa, H., Suzuki, S., Yamane, K., Doi, Y., Shibata, N., Kato, H., Shibayama, K. & Arakawa, Y. (2005).** Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *J Clin Microbiol* **43**(6), 2551-2558.
- Yan, J. J., Wu, J. J., Tsai, S. H. & Chuang, C. L. (2004).** Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli. *Diagn Microbiol Infect Dis* **49**(1), 5-11.

**Figure 1 Schematic representation of results from resazurin microtitre plate assay at 6**

**h.** CTX = cefotaxime; CAZ=ceftazidime; CA=clavulanic acid (4  $\mu$ g/ml); CX = cloxacillin (200  $\mu$ g/ml); EDTA = ethylenediaminetetraacetic acid (0.5 mM).



**Table 1.** Bacterial strains used in this investigation and results of phenotypic  $\beta$ -lactamase detection at 6 h using CTX -based<sup>ABCD</sup> and CAZ-based<sup>abcd</sup> assays.

Strains	Resistance Mechanism	MICs of CTX -based ( $\mu\text{g/ml}$ )				MICs of CAZ -based ( $\mu\text{g/ml}$ )				Phenotypic results
		A	B	C	D	a	b	c	d	
* <i>E. coli</i> ATCC 25922	Negative control	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	None
<i>K. pneumoniae</i> 2001	DHA-1	4	$\geq 256$	8	4	8	$\geq 256$	16	8	AmpC
<i>E. coli</i> 2002	DHA-1	4	32	4	4	16	$\geq 256$	16	16	AmpC
<i>E. coli</i> 2003	AmpC	$\leq 0.06$	0.25	$\leq 0.06$	$\leq 0.06$	0.125	1	0.125	0.125	AmpC
<i>E. coli</i> 2004	CMY-2	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	64	$\leq 0.06$	$\leq 0.06$	AmpC
<i>E. coli</i> 2005	AmpC	$\leq 0.06$	2	$\leq 0.06$	$\leq 0.06$	0.125	4	0.125	0.125	AmpC
<i>E. coli</i> 2006	CMY-2	0.25	8	0.125	0.125	0.25	4	0.25	0.25	AmpC
<i>E. aerogenes</i> 2007	ACT-31	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	4	$\leq 0.06$	$\leq 0.06$	AmpC
<i>E. cloacae</i> 2008	FOX	$\leq 0.06$	16	$\leq 0.06$	$\leq 0.06$	0.125	32	0.125	0.125	AmpC
<i>E. cloacae</i> 2009	ACR-32	0.125	64	0.125	0.125	0.125	32	0.125	0.125	AmpC
<i>M. morgani</i> 2010	AmpC	2	64	2	2	8	$\geq 256$	8	8	AmpC
<i>E. cloacae</i> 2011	AmpC	$\leq 0.06$	64	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	AmpC
<i>C. freundii</i> 2026	CMY-112	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	AmpC
<i>K. pneumoniae</i> 2020	FOX	$\leq 0.06$	2	$\leq 0.06$	$\leq 0.06$	0.5	16	0.5	0.5	AmpC
<i>E. coli</i> 2021	FOX-3	$\leq 0.06$	0.5	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	8	0.125	0.125	AmpC
<i>E. cloacae</i> 2022	ACT-32	4	128	4	4	2	$\geq 256$	2	2	AmpC
* <i>E. cloacae</i> BAA-1143	ACT-32	4	128	4	4	2	128	4	4	AmpC
<i>E. coli</i> 1004	TEM-214	64	0.125	0.125	0.125	16	0.25	0.25	0.125	ESBL
<i>E. coli</i> 1005	CTX-M-3	1	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	0.5	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>E. coli</i> 1006	CTX-M-3	64	0.125	$\leq 0.06$	$\leq 0.06$	1	0.125	0.125	0.125	ESBL
<i>E. coli</i> 1008	CTX-M-3	$\geq 256$	0.25	0.125	0.125	64	1	0.5	0.5	ESBL
<i>E. coli</i> 1009	TEM	32	0.125	$\leq 0.06$	$\leq 0.06$	4	0.125	0.125	0.125	ESBL
<i>K. pneumoniae</i> 1010	CTX-M-15,SHV-27	64	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	16	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>K. pneumoniae</i> 1012	SHV-27,TEM-53	64	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	0.125	0.125	0.125	ESBL
<i>K. pneumoniae</i> 1013	SHV-27	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	0.5	0.5	0.5	ESBL
<i>K. pneumoniae</i> 1015	SHV-27,TEM-71	16	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	8	0.125	0.125	0.125	ESBL
* <i>E. coli</i> 13352	TEM-10	1	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	128	0.5	0.5	0.5	ESBL
* <i>E. coli</i> 13353	CTX-M-15	128	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>K. pneumoniae</i> 1021	SHV-18	128	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>K. pneumoniae</i> 1022	SHV-27,TEM-115	32	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	16	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>K. pneumoniae</i> 1023	SHV-27,CTX-M-15	64	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	16	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	ESBL
<i>E. cloacae</i> 3007	CTX-M-9, MIR-1 ACT-1	16	64	$\leq 0.06$	$\leq 0.06$	1	32	$\leq 0.06$	$\leq 0.06$	AmpC+ESBL
<i>E. cloacae</i> 3009	TEM-214,SHV-12+ ACT	16	1	0.125	$\leq 0.06$	4	0.25	$\leq 0.06$	$\leq 0.06$	AmpC+ESBL
<i>E. aerogenes</i> 3022	SHV-12,CTX-M-9+ ACT-32	2	32	$\leq 0.06$	$\leq 0.06$	0.5	2	0.25	0.25	AmpC+ESBL
<i>E. coli</i> 3003	CTX-M-9+AmpC	4	32	0.125	$\leq 0.06$	32	16	0.125	$\leq 0.06$	AmpC+ESBL
<i>C. freundii</i> 3004	CTX-M-3+AmpC	2	32	$\leq 0.06$	$\leq 0.06$	0.25	4	$\leq 0.06$	$\leq 0.06$	AmpC+ESBL
<i>C. freundii</i> 3005	CTX-M-3+ ACT-1	4	32	$\leq 0.06$	$\leq 0.06$	32	4	0.25	0.25	AmpC+ESBL
<i>K. ozaenae</i> 4031	IMP-1	$\leq 0.06$	0.125	32	$\leq 0.06$	0.5	0.5	128	$\leq 0.06$	MBL
<i>K. pneumoniae</i> 4033	VIM-1+SHV-102	4	$\leq 0.06$	32	$\leq 0.06$	128	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL+ESBL
<i>K. pneumoniae</i> 4034	VIM-1+SHV-12	8	$\leq 0.06$	8	$\leq 0.06$	128	$\leq 0.06$	128	$\leq 0.06$	MBL+ESBL
<i>K. pneumoniae</i> 4036	NDM-1	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>K. pneumoniae</i> 4025	VIM-type	0.125	0.125	$\geq 256$	0.125	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>E. cloacae</i> 4004	NDM-1	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>K. pneumoniae</i> 4017	VIM-type	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>K. pneumoniae</i> 4023	NDM-1	0.125	0.125	1	0.125	$\leq 0.06$	$\leq 0.06$	2	$\leq 0.06$	MBL
<i>K. pneumoniae</i> 4024	NDM-1	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>E. coli</i> 4011	NDM-1	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	$\leq 0.06$	$\leq 0.06$	$\geq 256$	$\leq 0.06$	MBL
<i>E. cloacae</i> 4005	NDM	8	8	$\geq 256$	4	2	2	$\geq 256$	1	MBL

CTX= cefotaxime; CAZ= ceftazidime; CA= clavulanic acid (4  $\mu\text{g/ml}$ ); CX=cloxacillin (200  $\mu\text{g/ml}$ ); EDTA = ethylenediaminetetraacetic acid (0.5mM); A (a) = CTX (CAZ)+ CX+EDTA; B (b) = CTX(CAZ)+CA+EDTA; C (c) = CTX(CAZ)+CA+CX; D (d) = CTX (CAZ)+CA+CX+EDTA. \* control strain



**Table 2** Interpretation criteria of ceftazidime (CAZ)-based and cefotaxime (CTX)-based detection using resazurin microtitre plate assay.

<b>MIC ratio <math>\geq 8</math></b>	<b>ESBL</b>	<b>AmpC</b>	<b>MBL</b>
A/D or a/d	+	-	-
B/D or b/d	-	+	-
C/D or c/d	-	-	+
A/D or a/d and B/D or b/d	+	+	-
A/D or a/d and C/D or c/d	+	-	+
B/D or b/d and C/D or c/d	-	+	+
A/D or a/d and B/D or b/d and C/D or c/d	+	+	+

A (a) = CTX (CAZ)+ CX+EDTA

B (b) = CTX(CAZ)+CA+EDTA

C (c) = CTX(CAZ)+CA+CX

D (d) = CTX (CAZ)+CA+CX+EDTA